OUR PIPELINE IS POISED TO DELIVER NOW AND IN THE FUTURE

Research engine is targeting 10-12 IND filings in FY21

TARGET APPROVAL	WAVE 1[1] FY21	WAVE 1[1] FY22	WAVE 1[1] FY23	WAVE 1[1] FY24	CLINICAL-STAGE NMEs / WAVE 2[2] FY25 and Beyond			
ONCOLOGY	**mobocertinib** *2L NSCLC with EGFR exon 20 insertion mutation*[3]	**pevonedistat** *HR-MDS*	**mobocertinib** *1L NSCLC with EGFR exon 20 insertion mutation*	**pevonedistat** *Unfit AML*[5] **TAK-007** *CD19+ hematologic malignancies*	**TAK-981** *Multiple cancers* **TAK-573** *R/R MM*	**TAK-676** *Solid tumors* **TAK-605** *Multiple cancers*	**TAK-252** *Solid tumors* **TAK-186** *EGFR Solid Tumor*	**TAK-102** *Multiple cancers* **TAK-940** *CD19+ hematologic malignancies*
RARE GENETICS & HEMATOLOGY	**maribavir** *R/R CMV infect. in transplant*	**TAK-609** *Hunter CNS (IT)*[6]	**maribavir** *1L CMV infect. in HSCT* **TAK-755** *cTTP*	**TAK-611** *MLD (IT)*	**TAK-755** *iTTP, SCD*	**mezagitamab** *MG, ITP*	**TAK-607** *Complications of prematurity*	
NEUROSCIENCE			**soticlestat** *DS* **soticlestat** *LGS*	**Orexin 2R-ag** *(TAK-994/TAK-925) Narcolepsy T1*	**Orexin 2R-ag** *(TAK-994/TAK-861/TAK-925) NT2, IH, Additional Indications* **TAK-071** *Parkinson's Disease*	**TAK-341** *Parkinson's Disease*	**TAK-831**[7] *CIAS NS* **TAK-041**[7] *Anhedonia in MDD*	**TAK-653**[7] *TRD*
GASTRO-ENTEROLOGY	**Eohilia**[4] *EoE Approval date TBD*				**TAK-999** *AAT Liver Disease* **TAK-906** *Gastroparesis*	**TAK-671** *Acute Pancreatitis* **TAK-954** *POGD*	**TAK-062** *Celiac Disease* **TAK-951** *Nausea & vomiting*	**TAK-101** *Celiac Disease* **TAK-039** *Hepatic encephalopathy*	**sibofimloc** *Crohn's Disease (post-op and ileitis)* **TAK-510** *Nausea & vomiting*
VACCINES	**TAK-003** *Dengue Vaccine* **TAK-019** *Novavax COVID-19 Vaccine (JP)* **TAK-919** *Moderna COVID-19 Vaccine (JP)*				**TAK-426** *Zika Vaccine*	**TAK-214** *Norovirus Vaccine*		

● Breakthrough and/or Fast Track Designations
● China Breakthrough and/or Japan SAKIGAKE Designation
Orphan potential in at least one indication
Orexin franchise
Additions in Q4: TAK-861, TAK-186, TAK-510
COVID-19 Vaccines

1. Projected approval dates depend on data read-outs; some WAVE 1 target approval dates assume accelerated approval
2. Certain WAVE 2 programs may be accelerated into WAVE 1 depending on future data read outs
3. Approval date assumes filing on Phase 2 data
4. In active discussions with the FDA. Projected approval subject to outcome of discussions
5. COVID-19 related shift in enrollment now suggests regulatory filing in FY24 and potential approval FY25
6. Filing of TAK-609 is subject to feedback from FDA on the ongoing extension trial and may change
7. Partnership with Neurocrine Biosciences
8. Timeline changes: Eohilia (FY21), TAK-609 (FY22), maribavir 1L (FY23), TAK-611 (FY24)

Takeda's Fiscal Year ends March 31 of the following year; e.g.,"FY20" refers to the twelve-month period ending March 31, 2021.
All timelines are approximate estimates of May 11, 2021. For glossary of disease abbreviations please refer to appendix.

MAXIMIZING THE VALUE OF OUR GLOBAL AND REGIONAL BRANDS

	PHASE 1 & 2	PHASE 3	FILED
ONCOLOGY		**NINLARO®** Proteasome inhibitor Maint. ND MM post-SCT (US, EU) **NINLARO®** Proteasome inhibitor Maint. ND MM no SCT (US, EU, CN) **ICLUSIG®** BCR-ABL inhibitor FL Ph+ ALL (US) **ALUNBRIG®** ALK inhibitor 2L ALK+NSCLC H2H with alectinib (GL) **Cabozantinib** *Exelixis* VEGFR/RTK inhibitor mCRPC combo w/atezolizumab (JP) **Cabozantinib** *Exelixis* VEGFR/RTK inhibitor 2L mNSCLC combo w/atezolizumab (JP)	✓ **ALUNBRIG®** ALK inhibitor 1L & 2L ALK+NSCLC (JP, CN) **NINLARO®** Proteasome inhibitor Maint. ND MM no SCT (JP) ✓ **ADCETRIS®** *Seattle Genetics* CD30 ADC CTCL (CN) **Cabozantinib** *Exelixis* VEGFR/RTK inhibitor 1L RCC combo w/nivolumab (JP)
RARE GENETICS & HEMATOLOGY	**NATPARA®** PTH replacement Hypothyrodism (JP)	**TAKHZYRO®** Anti-kallikrein mAb HAE pediatric (GL) **TAKHZYRO®** Anti-kallikrein mAb BMA (GL) **ADYNOVATE®** Pediatric HemA (EU) **VONVENDI®** vWF replacement vWD Pediatric on-demand & surgery(GL)	**TAKHZYRO®** Anti-kallikrein mAb HAE (JP) **VONVENDI®** vWF replacement vWD Adult Prophylaxis (GL)
NEUROSCIENCE			
GASTRO-ENTEROLOGY	**ENTYVIO®** α4β7 mAb Pediatric UC/CD (GL)	**ENTYVIO®** α4β7 mAb SubQ CD (US, JP) **ENTYVIO®** α4β7 mAb GvHD Prophylaxis (EU, JP) **Vonoprazan** PCAB H. Pylori (CN) **ALOFISEL®** mesenchymal stem cells Perianal Fistulas in CD (US)	**ALOFISEL®** mesenchymal stem cells Perianal Fistulas in CD (JP) **ENTYVIO®** α4β7 mAb SubQ UC (US, JP) **Vonoprazan** PCAB Oral disintegrated tablet formulation (JP) **Vonoprazan** PCAB Reflex Esophagitis Maintenance (CN) **Vonoprazan** PCAB Duodenal ulcer (CN) **GATTEX®** GLP-2R agonist Pediatric-SBS (JP) **GATTEX®** GLP-2R agonist Adult-SBS (JP)
VACCINES			
PDT		**CUVITRU®** IgG 20% (human) subcutaneous PID (JP) **HYQVIA®** *Halozyme* IgG 10% + Recombinant Human Hyaluronidase CIDP (US, EU) **HYQVIA®** *Halozyme* IgG 10% + Recombinant Human Hyaluronidase Pediatric PID (US, EU[1])	

● Orphan Drug Designation (in any region / indication for a given asset)
✓ Approved since Q3 FY20
● Potential for registration enabling Ph-2 study
✗ Discontinued/deprioritized

Status as of May 11, 2021; region abbreviations: GL = global (USA, Europe, Japan, China). Pipeline not all inclusive; programs also ongoing in other Therapeutic Areas

1. Ph4 study completed Q4 FY20